{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:38:05Z","timestamp":1793144285995,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cjco.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:16:56Z","timestamp":1736381816000},"page":"493-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Intersection of Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: Recent Insights in a Challenging Area"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-2316","authenticated-orcid":false,"given":"Michael","family":"Heffernan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2025.01.001_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.trsl.2013.05.001","article-title":"Chronic obstructive pulmonary disease and cardiovascular disease","volume":"162","author":"Bhatt","year":"2013","journal-title":"Trans Res"},{"key":"10.1016\/j.cjco.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CRD.0b013e318279e907","article-title":"Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review","volume":"21","author":"Ghoorah","year":"2013","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cjco.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MCP.0000000000000748","article-title":"Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly","volume":"27","author":"Leitao Filho","year":"2021","journal-title":"Curr Opin Pulmon Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1753465817750524","article-title":"Defining the relationship between COPD and CVD: What are the implications for clinical practice?","volume":"12","author":"Morgan","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.cjco.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","article-title":"Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease","volume":"186","author":"Divo","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"180057","DOI":"10.1183\/16000617.0057-2018","article-title":"Cardiovascular disease and COPD: dangerous liaisons?","volume":"27","author":"Rabe","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cjco.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1378\/chest.12-2847","article-title":"Cardiovascular comorbidity in COPD: systematic literature review","volume":"144","author":"M\u00fcllerova","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1164\/rccm.201604-0690SO","article-title":"Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care","volume":"194","author":"Roversi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1183\/09031936.00133805","article-title":"Mortality in COPD: role of comorbidities","volume":"28","author":"Sin","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjco.2025.01.001_bib10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/thx.2006.072348","article-title":"Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee","volume":"62","author":"McGarvey","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.cjco.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chest.2023.08.014","article-title":"2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD","volume":"164","author":"Bourbeau","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2025.01.001_bib12","first-page":"459","article-title":"Should we treat chronic obstructive pulmonary disease as a cardiovascular disease?","volume":"9","author":"Rabinovich","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"816843","DOI":"10.3389\/fmed.2022.816843","article-title":"Triple therapy in COPD: Can we welcome the reduction in cardiovascular risk and mortality?","volume":"9","author":"Solidoro","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cjco.2025.01.001_bib14","first-page":"101","article-title":"The use of \u03b2-blockers in heart failure with reduced ejection fraction","volume":"8","author":"Masarone","year":"2021","journal-title":"J\u00a0Cardiovasc Dev Dis"},{"key":"10.1016\/j.cjco.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events: a post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s11606-018-4518-3","article-title":"Incidence of acute cardiovascular event after acute exacerbation of COPD","volume":"33","author":"Goto","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib19","first-page":"1299","article-title":"Cardiovascular diseases in COPD: from diagnosis and prevalence to therapy","volume":"13","author":"Papaporfyriou","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.cjco.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1378\/chest.128.4.2068","article-title":"COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program","volume":"128","author":"Sidney","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1378\/chest.11-2413","article-title":"Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de Medicina Interna (ESMI) Study","volume":"142","author":"Almagro","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/eurjhf\/hfs009","article-title":"Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF","volume":"14","author":"Mentz","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"315.e7-14","DOI":"10.1016\/j.jcrc.2013.11.011","article-title":"Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life","volume":"29","author":"Matamis","year":"2014","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cjco.2025.01.001_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1183\/09031936.00044411","article-title":"Unrecognised ventricular dysfunction in COPD","volume":"39","author":"Macchia","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjco.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurjhf\/hfq157","article-title":"Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease","volume":"12","author":"Kwon","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2025.01.001_bib27","first-page":"36","article-title":"Association of chronic obstructive pulmonary disease with arrhythmia risks: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","article-title":"Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial","volume":"6","author":"Hohlfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0035-1556063","article-title":"Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management","volume":"36","author":"Putcha","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/15412555.2011.636555","article-title":"Insights into COPD comorbidities from the OLIN study and other large databases","volume":"8","author":"Mapel","year":"2011","journal-title":"COPD"},{"key":"10.1016\/j.cjco.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1081\/COPD-200050671","article-title":"Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration medical system, 1991\u20131999","volume":"2","author":"Mapel","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.cjco.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.rmed.2009.09.019","article-title":"Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study","volume":"104","author":"Almagro","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2147\/COPD.S84482","article-title":"Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study","volume":"10","author":"Almagro","year":"2015","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.cjco.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1183\/09031936.03.00051502","article-title":"Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study","volume":"1","author":"Buch","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjco.2025.01.001_bib35","first-page":"2908","article-title":"Atrial fibrillation in the acute, hypercapnic exacerbations of COPD","volume":"18","author":"Terzano","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cjco.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2019.01.074","article-title":"The burden and impact of arrhythmia in chronic obstructive pulmonary disease: insights from the National Inpatient Sample","volume":"281","author":"Desai","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1540-8167.2012.02448.x","article-title":"Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation","volume":"24","author":"Gu","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/europace\/eur406","article-title":"Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: The Euro Heart Survey","volume":"14","author":"Pisters","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.cjco.2025.01.001_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0272-5231(03)00144-8","article-title":"Amiodarone pulmonary toxicity","volume":"25","author":"Camus","year":"2004","journal-title":"Clin. Chest Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ensci.2016.11.007","article-title":"Prevalence and influence of chronic obstructive pulmonary disease on stroke outcomes in hospitalized stroke patients","volume":"6","author":"Lekoubou","year":"2017","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.cjco.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.annepidem.2005.04.008","article-title":"Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients","volume":"16","author":"Curkendall","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0002-9343(85)90457-7","article-title":"Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease","volume":"78","author":"Shepard","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijcard.2014.03.140","article-title":"Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort","volume":"173","author":"Yin","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/ggi.12575","article-title":"Influence of comorbidities on the efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease","volume":"16","author":"Higashimoto","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.cjco.2025.01.001_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/15412555.2014.974734","article-title":"Prevalence of co-morbidities and severity of COPD","volume":"12","author":"Battaglia","year":"2015","journal-title":"COPD"},{"key":"10.1016\/j.cjco.2025.01.001_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2213-2600(12)70060-7","article-title":"Chronic obstructive pulmonary disease and comorbidities","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/00015385.2018.1559485","article-title":"Heart failure and chronic obstructive pulmonary disease: a review","volume":"75","author":"Horodinschi","year":"2020","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib48","doi-asserted-by":"crossref","first-page":"7961","DOI":"10.2147\/IJGM.S295467","article-title":"Optimal management of heart failure and chronic obstructive pulmonary disease: clinical challenges","volume":"15","author":"Cuthbert","year":"2022","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003566.pub2","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjco.2025.01.001_bib50","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1164\/rccm.200803-384OC","article-title":"Impact of cardioselective \u03b2-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis","volume":"178","author":"Van Gestel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib51","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1007784109255","article-title":"Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors","volume":"13","author":"Smith","year":"1999","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjco.2025.01.001_bib53","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2006.04.039","article-title":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease","volume":"47","author":"Mancini","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/15412555.2015.1099620","article-title":"Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis","volume":"13","author":"Pavasini","year":"2016","journal-title":"COPD"},{"key":"10.1016\/j.cjco.2025.01.001_bib55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1164\/rccm.201208-1565OC","article-title":"Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease","volume":"187","author":"Ekstr\u00f6m","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib56","doi-asserted-by":"crossref","unstructured":"Andell P, James SK, Cannon CP, et\u00a0al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. J Am Heart Assoc 4:e002490.","DOI":"10.1161\/JAHA.115.002490"},{"key":"10.1016\/j.cjco.2025.01.001_bib57","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1378\/chest.12-1770","article-title":"Combination antihypertensive therapy among patients with COPD","volume":"143","author":"Herrin","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2025.01.001_bib58","article-title":"Beta-blockers reduce severe exacerbation in patients with mild chronic obstructive pulmonary disease with atrial fibrillation: a population-based cohort study","volume":"10","author":"Lin","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.cjco.2025.01.001_bib59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ejhf.2350","article-title":"Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES","volume":"24","author":"Yeoh","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2025.01.001_bib60","doi-asserted-by":"crossref","first-page":"L315","DOI":"10.1152\/ajplung.00238.2021","article-title":"Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model","volume":"322","author":"Lu","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.cjco.2025.01.001_bib61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejphar.2013.08.019","article-title":"Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models","volume":"718","author":"Lieber","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cjco.2025.01.001_bib62","doi-asserted-by":"crossref","unstructured":"Liczek M, Panek I, Damia\u0144ski P, et\u00a0al. Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease [e-pub ahead of print]. Adv Respir Med https:\/\/doi.org\/10.5603\/ARM.a2018.0028.","DOI":"10.5603\/ARM.a2018.0028"},{"key":"10.1016\/j.cjco.2025.01.001_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12020-021-02644-x","article-title":"Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"73","author":"Qiu","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.cjco.2025.01.001_bib64","unstructured":"Jasleen B, Vishal GK, Sameera M, et\u00a0al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk. Cureus 15:e33939."},{"key":"10.1016\/j.cjco.2025.01.001_bib65","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1164\/rccm.202307-1122OC","article-title":"Temporal risk of non-fatal cardiovascular events post COPD exacerbation: a population-based study","volume":"209","author":"Graul","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"Cardiovascular events in patients with COPD: TORCH Study results","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.cjco.2025.01.001_bib67","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS Trial of Budesonide\/Glycopyrrolate\/Formoterol for Chronic Obstructive Pulmonary Disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib69","first-page":"1635","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"375","author":"Vestbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib70","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2025.01.001_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221113647","article-title":"Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"M\u00fcllerov\u00e1","year":"2022","journal-title":"Ther Adv Respir Dis"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:56:14Z","timestamp":1744977374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X25000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2589790X25000010"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2025.01.001","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Intersection of Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: Recent Insights in a Challenging Area","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}